AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25742614 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Audiological Rehabilitation (GAR) program
Number of subjects: 24
Study 25742614 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 24
Study 24074707 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Peg-IFNa-2a) for 48 weeks
Number of subjects: 57
Study 24074707 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV) continued therapy
Number of subjects: 57
Study 21877028 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 44
Study 21877028 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 44
Study 18777192 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 34614
Study 18777192 — intervention group
Group type: COMPARATOR
Intervention: Standard Chest X-ray (CXR)
Number of subjects: 34614
Study 16319906 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (160 mg)
Number of subjects: 24
Study 15478553 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pneumothorax (AP) during chemotherapy with reserve drugs
Number of subjects: 43
Study 15478553 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 43
Study 11014757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire Ensemble (FE)
Number of subjects: 18
Study 11014757 — intervention group
Group type: COMPARATOR
Intervention: Sports Ensemble (SE)
Number of subjects: 18
Study 9115056 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 12
Study 1343270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy, ACE inhibitors, methyldopa
Number of subjects: 104
Study 1343270 — intervention group
Group type: COMPARATOR
Intervention: Vasodilators (minoxidil, hydralazine)
Number of subjects: 104
Study 1343270 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blockers
Number of subjects: 104
Study 1343270 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 104
Study 3909336 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1-g intramuscular dose of aztreonam for acute uncomplicated cystitis
Number of subjects: 681
Study 3909336 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple parenteral doses of aztreonam (usually a five-day course of 1 g two or three times daily)
Number of subjects: 681
Study 3909336 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose therapy of aztreonam
Number of subjects: 681
Study 3909336 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam
Number of subjects: 681
Study 3909336 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose therapy of aztreonam in patients with multiply drug-resistant bacteria
Number of subjects: 681
Study 31729087 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 98
Study 31729087 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (Net-En)
Number of subjects: 98
Study 31729087 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (CU-IUD)
Number of subjects: 98
Study 30665436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) plus probiotic (8 x 10^9 CFU/day)
Number of subjects: 60
Study 30665436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and probiotic co-supplementation
Number of subjects: 60
Study 30665436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29553453 — intervention group
Group type: EXPERIMENTAL
Intervention: UNRWA health centre services for non-communicable diseases
Number of subjects: 400
Study 29553453 — intervention group
Group type: EXPERIMENTAL
Intervention: General impressions, accessibility, communication, interpersonal relationships
Number of subjects: 400
Study 29553453 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical quality of services, clinic environment, convenience of services
Number of subjects: 400
Study 29553453 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (unmarried, working, living in southern Gaza, educated, received educational materials)
Number of subjects: 400
Study 29553453 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific health provider, receiving all medications from UNRWA, not turned away from clinic
Number of subjects: 400
Study 29553453 — intervention group
Group type: COMPARATOR
Intervention: Sex, age, presence of disability, presence of complications, control status, kind of non-communicable disease, type of treatment provided, duration of non-communicable disease
Number of subjects: 400
Study 27735912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor + ASA
Number of subjects: 0
Study 27735912 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel + ASA
Number of subjects: 0
Study 24508026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly for 6 months)
Number of subjects: 64
Study 24508026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23049758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 23049758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19296845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy product containing Bifidobacterium lactis DN-173 010
Number of subjects: 160
Study 19296845 — intervention group
Group type: COMPARATOR
Intervention: Control product (acidified milk without ferments, toilet training, bowel diary)
Number of subjects: 160
Study 17671933 — intervention group
Group type: EXPERIMENTAL
Intervention: Small pupil group (pupil size of 2.5-2.9 mm; 45 subjects)
Number of subjects: 62
Study 17671933 — intervention group
Group type: COMPARATOR
Intervention: Large pupil group (pupil size of 3-5 mm; 17 subjects)
Number of subjects: 62
Study 17671933 — intervention group
Group type: EXPERIMENTAL
Intervention: Small pupil group
Number of subjects: 62
Study 17671933 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 62
Study 15233669 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 135 microg/wk
Number of subjects: 639
Study 15233669 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a 180 microg/wk
Number of subjects: 639
Study 15233669 — intervention group
Group type: COMPARATOR
Intervention: interferon alpha‐2a 3 MIU thrice weekly
Number of subjects: 639
Study 11581479 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use sterile catheters
Number of subjects: 10
Study 11581479 — intervention group
Group type: COMPARATOR
Intervention: Reuse of clean catheters
Number of subjects: 10
Study 9572829 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (135 mg/day)
Number of subjects: 37
Study 9572829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9572829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 8083793 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive oral hygiene training program (3.5 hours per child)
Number of subjects: 227
Study 8083793 — intervention group
Group type: EXPERIMENTAL
Intervention: Less comprehensive oral hygiene training program (1.5 hours per child)
Number of subjects: 227
Study 8083793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive program)
Number of subjects: 227
Study 2479963 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate combination chemotherapy and radiotherapy
Number of subjects: 151
Study 2479963 — intervention group
Group type: COMPARATOR
Intervention: Selective treatment (chemotherapy and/or radiotherapy as needed)
Number of subjects: 151
Study 781336 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin‐pectin suspension concentrate (Kao‐Con)
Number of subjects: 80
Study 781336 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate‐atropine liquid (Lomotil)
Number of subjects: 80
Study 781336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 781336 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin suspension
Number of subjects: 80
Study 781336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin suspension
Number of subjects: 80
Study 31280410 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (0.9% sodium chloride in 5% dextrose)
Number of subjects: 150
Study 31280410 — intervention group
Group type: COMPARATOR
Intervention: N/2 saline (0.45% sodium chloride in 5% dextrose)
Number of subjects: 150
Study 28167197 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training with 0% load
Number of subjects: 30
Study 28167197 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training with 5% load
Number of subjects: 30
Study 28167197 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training with 10% load
Number of subjects: 30
Study 28167197 — intervention group
Group type: COMPARATOR
Intervention: Control group (Treadmill with 0% load)
Number of subjects: 30
Study 25963586 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA conditioning (17% EDTA for 2 min prior to adhesive application)
Number of subjects: 48
Study 25963586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EDTA conditioning, placed according to manufacturer's instructions)
Number of subjects: 48
Study 23425732 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG‐guided prophylaxis with escalating low‐molecular weight heparin (LMWH) up to 5,000 IU twice daily with the addition of aspirin
Number of subjects: 50
Study 23425732 — intervention group
Group type: COMPARATOR
Intervention: 5,000 IU of LMWH daily (control)
Number of subjects: 50
Study 23425732 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with apheresis platelets
Number of subjects: 50
Study 22087615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing standardized lemon verbena extract (14% verbascoside, w/w) and fish oil omega-3 fatty acid
Number of subjects: 45
Study 22087615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19133801 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 50
Study 19133801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 50
Study 16820316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical SNAGs
Number of subjects: 16
Study 16820316 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16
Study 16820316 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 15017517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g, 10 mL suspension, twice a day for 6 weeks)
Number of subjects: 50
Study 15017517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15017517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 50
Study 10834412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime-only insulin pump therapy
Number of subjects: 10
Study 9076405 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain ascorbic acid (250 mg BID)
Number of subjects: 59
Study 9076405 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release ascorbic acid (250 mg BID)
Number of subjects: 59
Study 9076405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8364279 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskhaler
Number of subjects: 20
Study 8364279 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 20
Study 8364279 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 20
Study 2432041 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheologically active substances (Dextran 40, hydroxyethyl starch 40/0.5)
Number of subjects: 400
Study 2432041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive and metabolically active substances (naftidrofurylhydrogenoxalate, Vinpocetin, betahistine, pentoxifylline, flunaricine, Regeneresen AU)
Number of subjects: 400
Study 2432041 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 400
Study 2432041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation
Number of subjects: 400
Study 28553791 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed training
Number of subjects: 2897
Study 28553791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2897
Study 28553791 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2897
Study 28553791 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 2897
Study 26504907 — intervention group
Group type: COMPARATOR
Intervention: Traditional inferior alveolar nerve block (IANB)
Number of subjects: 91
Study 26504907 — intervention group
Group type: EXPERIMENTAL
Intervention: IANB using a computer-controlled local anesthetic delivery system (CCLAD)
Number of subjects: 91
Study 26504907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental anesthesia (ILA) using CCLAD
Number of subjects: 91
Study 23702047 — intervention group
Group type: COMPARATOR
Intervention: Hygiene promotion and water treatment (HP&WT) and sanitation improvements in 'water-available' schools
Number of subjects: 0
Study 23702047 — intervention group
Group type: COMPARATOR
Intervention: Hygiene promotion and water treatment (HP&WT) in 'water-available' schools
Number of subjects: 0
Study 23702047 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-supply improvement, HP&WT, and sanitation in 'water-scarce' schools
Number of subjects: 0
Study 22836448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg)
Number of subjects: 171
Study 22836448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 20050880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg intravenous treatment for 21 days
Number of subjects: 30
Study 20050880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17397307 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) for root exposure without NCCL (group 1)
Number of subjects: 59
Study 17397307 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) with resin modified glass ionomer cement (RMGI) restoration for root exposure with NCCL (group 2)
Number of subjects: 59
Study 17397307 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) with microfilled resin composite (MRC) restoration for root exposure with NCCL (group 3)
Number of subjects: 59
Study 17397307 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups 2 and 3
Number of subjects: 59
Study 12759885 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS (5 mg/d)
Number of subjects: 50
Study 12759885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 50
Study 10950834 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with local anesthetic
Number of subjects: 16
Study 10950834 — intervention group
Group type: COMPARATOR
Intervention: Control (no epidural blockade)
Number of subjects: 16
Study 9051543 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (bolus 0.015 mg/kg followed by an infusion 0.003 mg/kg/hr)
Number of subjects: 44
Study 9051543 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone (bolus 0.15 mg/kg followed by an infusion 0.03 mg/kg/hr)
Number of subjects: 44
Study 9051543 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxycodone (same dose as in the epidural group)
Number of subjects: 44
Study 8112441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol, 10 mg once daily
Number of subjects: 70
Study 8112441 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline, 5 mg controlled release twice daily
Number of subjects: 70
Study 2877127 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg indenolol once a day for 14 days
Number of subjects: 0
Study 2877127 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg indenolol once a day for 14 days
Number of subjects: 0
Study 2877127 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the 14 day run-in period
Number of subjects: 0
Study 29413983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitra™
Number of subjects: 35
Study 29413983 — intervention group
Group type: COMPARATOR
Intervention: Dried Blood Spots (DBS)
Number of subjects: 35
Study 27239902 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral biographical disclosure
Number of subjects: 198
Study 27239902 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured biographical writing
Number of subjects: 198
Study 27239902 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diary
Number of subjects: 198
Study 27239902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 23859485 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated collagen cross-linking (CXL)
Number of subjects: 36
Study 23859485 — intervention group
Group type: COMPARATOR
Intervention: Non-operative eyes (control)
Number of subjects: 36
Study 22323576 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine mouth spray (n=318)
Number of subjects: 479
Study 22323576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=161)
Number of subjects: 479
Study 19962270 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 88
Study 19962270 — intervention group
Group type: COMPARATOR
Intervention: Transverse incision
Number of subjects: 88
Study 18949838 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful constipation (PC)
Number of subjects: 231
Study 18949838 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain constipation (HPC)
Number of subjects: 231
Study 15986443 — intervention group
Group type: EXPERIMENTAL
Intervention: Current injectable hormonal contraceptive use
Number of subjects: 5060
Study 15986443 — intervention group
Group type: EXPERIMENTAL
Intervention: Current injectable hormonal contraceptive use among women with HPV16 infection
Number of subjects: 5060
Study 15986443 — intervention group
Group type: COMPARATOR
Intervention: Former oral contraceptive use
Number of subjects: 5060
Study 15986443 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive use, Norplant use, history of pregnancy, age at first pregnancy, lifetime numbers of pregnancies and live births
Number of subjects: 5060
Study 12665083 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with repeated quit attempts
Number of subjects: 0
Study 12665083 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (whole group)
Number of subjects: 0
Study 12665083 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 0
Study 10852448 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 20
Study 10852448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8654467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam-containing ondansetron regimen
Number of subjects: 35
Study 8654467 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone
Number of subjects: 35
Study 1513608 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (15‐mg/kg/day oral suspension or 200‐mg capsule taken twice daily for 10 days)
Number of subjects: 233
Study 1513608 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK (20‐mg/kg/day oral suspension or 250‐mg capsule taken four times daily for 10 days)
Number of subjects: 233
Study 1513608 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 233
Study 1513608 — intervention group
Group type: COMPARATOR
Intervention: Penicillin VK
Number of subjects: 233
Study 1513608 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef and Penicillin VK
Number of subjects: 233
Study 6337473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethylsuccinate (40 mg/kg/day in divided doses) for five days
Number of subjects: 26
Study 6337473 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 26
Study 31869340 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly missed nursing care elements in the perinatal setting.
Number of subjects: 422
Study 31869340 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for commonly missed nursing care.
Number of subjects: 422
Study 31869340 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with commonly missed nursing care.
Number of subjects: 422
Study 29856768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (supervised training sessions three times weekly and home exercise once weekly)
Number of subjects: 55
Study 29856768 — intervention group
Group type: COMPARATOR
Intervention: Standard maternity care (control group)
Number of subjects: 55
Study 29856768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 55
Study 29856768 — intervention group
Group type: COMPARATOR
Intervention: Newborns of normal weight women (n = 20)
Number of subjects: 55
Study 26813468 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g Hawaiian spirulina daily for three months
Number of subjects: 40
Study 26813468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24817203 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial/ethnic match with therapist
Number of subjects: 224
Study 24817203 — intervention group
Group type: COMPARATOR
Intervention: Racial/ethnic mismatch with therapist
Number of subjects: 224
Study 21551226 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial hardship
Number of subjects: 431
Study 21551226 — intervention group
Group type: COMPARATOR
Intervention: No financial hardship (control group)
Number of subjects: 431
Study 21551226 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood poverty
Number of subjects: 431
Study 21551226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-cranial volume
Number of subjects: 431
Study 19458887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-drop (LD) exercise group performing single-leg drop-landings from 14 cm
Number of subjects: 42
Study 19458887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-drop (HD) exercise group performing single-leg drop-landings from 28 cm
Number of subjects: 42